A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer

Aflibercept, a recombinant fusion protein, is a potent inhibitor of vascular endothelial growth factor (VEGF)-A, VEGF-B, and the placental growth factor (PlGF). The present study was an open-label, sequential-cohort, dose-escalation trial of intravenous aflibercept administered every 2 weeks in comb...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Yoshino, Takayuki, Yamazaki, Kentaro, Yamaguchi, Kensei, Doi, Toshihiko, Boku, Narikazu, Machida, Nozomu, Onozawa, Yusuke, Asayama, Masako, Fujino, Tadahiro, Ohtsu, Atsushi
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Springer US 2012
Onderwerpen:
Phase I Studies
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3717157/
https://ncbi.nlm.nih.gov/pubmed/23179335
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-012-9895-6
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items